Hinova Pharmaceuticals (SHSE:688302) Equity-to-Asset : 0.92 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Hinova Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,326.10 Mil. Hinova Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was ¥1,434.44 Mil.

The historical rank and industry rank for Hinova Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

SHSE:688302' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.81 Med: 0.89 Max: 0.92
Current: 0.92

During the past 6 years, the highest Equity to Asset Ratio of Hinova Pharmaceuticals was 0.92. The lowest was -0.81. And the median was 0.89.

SHSE:688302's Equity-to-Asset is ranked better than
89.59% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs SHSE:688302: 0.92

Hinova Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Hinova Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Equity-to-Asset Chart

Hinova Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.81

0.83

0.80

0.91

0.92

Hinova Pharmaceuticals Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial												0.91	0.90	0.89	0.92	0.92

Competitive Comparison of Hinova Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Hinova Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hinova Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's Equity-to-Asset falls into.

Hinova Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Hinova Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1367.09	/	1491.565
	=

Hinova Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	1326.103	/	1434.439
	=

Hinova Pharmaceuticals (SHSE:688302) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Hinova Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals (SHSE:688302) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041

Website

http://www.hinovapharma.com

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals (SHSE:688302) Headlines

No Headlines